GlassScriptPhysician profile
Alejandro C Dizon
NPI 1225057193
$12,767.97
in general payments reported to CMS, 2019-2025
59 companies · $2,051 in 2025
The $2,051 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,215 · 2020: $1,646 · 2021: $1,866 · 2022: $1,378 · 2023: $1,968 · 2024: $1,645 · 2025: $2,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,663.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,787.56 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,509.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $891.67 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $887.01 | 2021-2025 | |
| Amgen INC. | $809.51 | 2019-2024 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $594.09 | 2019-2025 | Jardiance, Tradjenta, Glyxambi |
| Abbvie INC. | $557.15 | 2021-2025 | Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $548.88 | 2019-2025 | Arexvy |
| Amarin Pharma, INC. | $503.72 | 2019-2021 | |
| Lilly USA, LLC | $390.61 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sunovion Pharmaceuticals INC. | $326.78 | 2019-2021 | |
| Pfizer INC. | $319.83 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $292.56 | 2019-2024 | Verquvo, Gardasil 9, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $255.66 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $214.39 | 2020-2023 | Gvoke Hypopen |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $192.25 | 2024 | |
| Abbott Laboratories | $188.62 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Cequr Corporation | $169.01 | 2024-2025 | Cequr Simplicity |
| Insulet Corporation | $163.47 | 2023-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $162.01 | 2019-2024 | |
| Astellas Pharma US INC | $140.84 | 2019-2021 | |
| Daiichi Sankyo INC. | $132.61 | 2020-2023 | Injectafer |
| Dexcom, INC. | $128.19 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $126.83 | 2022 | |
| Verrica Pharmaceuticals INC. | $125.00 | 2025 | Ycanth |
| Eisai INC. | $108.70 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.03 | 2024-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $93.05 | 2023-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $92.16 | 2023-2025 | Rexulti |
| Insmed, INC. | $79.91 | 2025 | Arikayce, Brinsupri |
| Evoke Pharma, INC. | $70.56 | 2024 | |
| Exact Sciences Corporation | $66.31 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $66.04 | 2023-2025 | Watchman Flx, Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.61 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $50.47 | 2019-2021 | |
| Shield Therapeutics INC | $41.23 | 2023-2024 | |
| Lundbeck LLC | $37.85 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $37.02 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $35.12 | 2022-2025 | Zoryve |
| Mylan Specialty L.P. | $33.16 | 2021 | |
| Alexion Pharmaceuticals, INC. | $32.74 | 2023 | Strensiq |
| Alkermes, INC. | $30.54 | 2025 | Aristada, Lybalvi |
| Abiomed | $28.71 | 2024 | Impella |
| Sanofi Pasteur INC. | $22.85 | 2019 | |
| Radius Health, INC. | $22.43 | 2024 | |
| Cipher Pharmaceuticals US LLC | $21.65 | 2025 | Spinosad, Natroba |
| Endo Pharmaceuticals INC. | $20.97 | 2020 | |
| Tris Pharma INC | $20.55 | 2024 | Dyanavel Xr |
| Biogen, INC. | $19.06 | 2021 | |
| Eyevance Pharmaceuticals LLC | $18.59 | 2021 | |
| Hikma Pharmaceuticals USA | $18.59 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.14 | 2022 | |
| Neuronetics, INC. | $15.57 | 2025 | Neurostar Tms Therapy System |
| Allergan, INC. | $13.86 | 2019 | |
| Ethicon US, LLC | $13.40 | 2020 | |
| Cmp Pharma, INC. | $13.33 | 2022 | |
| Athena Bioscience, LLC | $12.84 | 2023 | Nexiclon Xr |
| Idorsia Pharmaceuticals US INC | $12.83 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Dizon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.